News & Publications for:

Eugene Johnson

Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson’s disease and nonhuman primate brains

Posted on October 24, 2011

Bartus RT, Herzog CD, Chu Y, Wilson A, Brown L, Siffert J, Johnson EM Jr, Olanow CW, Mufson EJ, Kordower JH (2011). Mov Disord, 26(1):27-36
Read More

Posted in: Publications Faculty:

Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson’s disease

Posted on October 20, 2011

Bartus RT, Brown L, Wilson A, Kruegel B, Siffert J, Johnson EM Jr, Kordower JH, Herzog CD (2011). Neurobiol Dis, 44(1):38-52
Read More

Posted in: Publications Faculty:

RET Signaling is Required for Survival and Normal Function of Non-Peptidergic Nociceptors

Posted on October 12, 2010

Golden JP, Hoshi M, Nassar MA, Enomoto H, Wood JN, Milbrandt J, Gereau RW 4th, Johnson EM Jr, Jain S (2010). J Neurosci, 30(11):3983-94. PMID:20237269 Read More

Posted in: Axon Injury & Repair, HPAN, Neurodegeneration, Neurogenetics, Publications, Therapeutics & Diagnostics Faculty: , , ,

Analysis of Ret knockin mice reveals a critical role for IKKs, but not PI 3-K, in neurotrophic factor-induced survival of sympathetic neurons

Posted on October 24, 2008

Encinas M, Rozen EJ, Dolcet X, Jain S, Comella JX, Milbrandt J, Johnson EM Jr (2008). Cell Death Differ, 15(9):1510-21
Read More

Posted in: Axon Injury & Repair, Publications Faculty: ,

RET is dispensable for maintenance and function of midbrain dopaminergic neurons

Posted on October 12, 2006

Jain S, Golden JP, Wozniak D, Pehek E, Johnson EM Jr, Milbrandt J (2006). J Neurosci, 26(43):11230-8 Read More

Posted in: Axon Injury & Repair, HPAN, Neurodegeneration, Neurogenetics, Publications Faculty: , , ,